Twist Bioscience in Partnership With Schrödinger

Twist Bioscience Corporation, a company offering synthetic DNA using its silicon platform, announced a collaboration with Schrödinger, Inc., a company focused on transforming the way therapeutics are discovered with a physics-based computational platform, to bring the 2 companies’ technology platforms together to discover new antibody therapeutics vs. G-protein coupled receptor (GPCR) targets.

Under the terms of the agreement, each company will contribute their individual expertise in a collaborative manner to discover novel antibody therapeutics. Specifically, Schrödinger will use its proprietary physics-based computational platform to model functional antibody segments that bind to a particular GPCR receptor.

Twist Biopharma, a division of Twist Bioscience, will then use its silicon-based DNA synthesis platform to generate a large number of precisely defined antibody sequences that can then be taken into PoC and pre-clinical development. The companies will collaborate on any commercial opportunities generated by the work together.

“This collaboration brings together two very important areas of drug discovery technology,” said Robert Abel, Ph.D., Schrödinger’s EVP of science. “Our physics-based platform enables detailed modeling of protein peptide interactions. Twist can then deploy its technology to incorporate such peptides into an antibody scaffold. Together, we believe we will be able to break new ground in antibody discovery and deliver next-gen therapeutics.“

“Through our internal efforts and key partnerships, we continue to e,nd our drug discovery capabilities,” commented Emily M. Leproust, Ph.D., CEO and co-founder, Twist Bioscience. “We started the company by offering our customers synthetic DNA in the form of genes and fragments, expanded our offering to take our synthetic DNA and elevate next-gen sequencing preparations, and now we are focused on leveraging our platform into antibody discovery. This partnership with Schrödinger builds on our strong foundation to further expand the benefit of our silicon-based DNA platform into therapeutics utilizing modeling.“